A clinical study of a cell-based MAGE-A3 active immunotherapy in advanced melanoma patients

Vincenzo Russo, Francesca Lunghi, Raffaella Fontana, Marco Bregni

Research output: Contribution to journalArticle


In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3+ melanoma patients were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were as-sessed by in vitro assay and delayed-type hypersensitivity skin testing.

Original languageEnglish
Pages (from-to)329-330
Number of pages2
JournalJournal of Cancer
Issue number1
Publication statusPublished - 2011



  • Immunotherapy
  • MAGE-A3
  • Melanoma

ASJC Scopus subject areas

  • Oncology

Cite this